Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 15/20 | 0.53 |
| ▸ | NPC1 | O15118 | 14/20 | 0.53 |
| ▸ | PKM | P14618 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4774462 | 0.92 | RAB9A (0.59) | RAB9ANPC1PKMPOLBHPGD | |
| Trifluoroacetic Acid SCHEMBL4768043 | 0.89 | NPC1 (0.54) | RAB9ANPC1PKMSLC2A1 | |
| SCHEMBL4768108 | 0.85 | NPC1 (0.51) | RAB9ANPC1PKMPOLBHPGD | |
| SCHEMBL4765960 | 0.85 | NR1H4 (0.52) | RAB9ANPC1PKMPOLBSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4776625 | 0.85 | NPC1 (0.50) | RAB9ANPC1PKMPOLBHPGD | |
| Hydrochloric Acid SCHEMBL4770084 | 0.84 | NR1H4 (0.51) | RAB9ANPC1PKMPOLBSMN1; SMN2 | |
| SCHEMBL4765305 | 0.84 | RAB9A (0.48) | RAB9ANPC1PKMPOLBHPGD | |
| Trifluoroacetic Acid SCHEMBL4774586 | 0.83 | MAPT (0.51) | RAB9ANPC1POLBHPGDSMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL4764992 | 0.83 | TP53 (0.51) | SMN1; SMN2MEN1KMT2AROCK1SLC2A1 | |
| Hydrochloric Acid SCHEMBL4774495 | 0.83 | RAB9A (0.47) | RAB9ANPC1PKMPOLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713778-B1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-16 | — | — | EP | claimed |
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | GLAXO GROUP LIMITED (GB) | 2007-03-15 | — | — | US | claimed |
| EP-1713778-B1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | HRH3, HRH4, HRH1 | RAB9A 2307/4885NPC1 2009/4885PKM 1656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.